Supplementary Figure 5 from A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer
Authors:
- Komal JhaveriKJKomal Jhaveri
- Dejan JuricDJDejan Juric
- Yoon-Sim YapYYYoon-Sim Yap
- Sara CrestaSCSara Cresta
- Rachel M. LaymanRLRachel M. Layman
- Francois P. DuhouxFDFrancois P. Duhoux
- Catherine TerretCTCatherine Terret
- Shunji TakahashiSTShunji Takahashi
- Jens HuoberJHJens Huober
- Nicole KundamalNKNicole Kundamal
- Qing ShengQSQing Sheng
- Alejandro BalbinABAlejandro Balbin
Open Access
- 4 November 2024
- other
- Published by American Association for Cancer Research (AACR)